Cystatin C is a potential predictor of unfavorable outcomes for cerebral ischemia with intravenous tissue plasminogen activator treatment: A multicenter prospective nested case–control study
Authors:
- 4 December 2020
- journal article
- research article
- Published by Wiley in European Journal of Neurology
- Vol. 28 (4) , 1265-1274
Abstract
Background This study is to explore whether Cystatin C could be used as a potential predictor of the clinical outcomes in acute ischemic stroke patients treated by intravenous tissue plasminogen activator. Methods We performed an observational study with a retrospective analysis of data from 125 acute ischemic stroke patients with intravenous thrombolysis. General linear models were applied to assess Cystatin C levels between groups with different outcomes; logistic regression analysis and receiver operating characteristic curves were adopted to identify the association between Cystatin C and the therapeutic effects. Results Compared with the Good&Sustained Benefit group (≥4 reduction in National Institutes of Health Stroke Scale or a score of 0‐1 at 24 hours and 7 days) and the Good Functional Outcome group (modified Rankin Scale 0‐2 at 90 days), serum Cystatin C baseline levels were increased in the non‐Good&Sustained Benefit and non‐Good Functional Outcome groups. Logistic regression analysis found that Cystatin C was an independent negative prognostic factor for Good&Sustained Benefit (odds ratio = 0.010, p = 0.005) and Good Functional Outcome (odds ratio = 0.011, p = 0.021) after adjustment for potential influencing factors. Receiver operating characteristic curves showed the Cystatin C‐involved combined models provided credible efficacy for predicting post‐90‐day favorable clinical outcomes (area under the curve = 0.86, p < 0.001). Conclusions Elevated serum Cystatin C is independently associated with unfavorable clinical outcomes after intravenous tissue plasminogen activator therapy in acute ischemic stroke. Our findings provide new insights into discovering potential mediators for neuropathological process or treatment in stroke.Keywords
This publication has 58 references indexed in Scilit:
- Early neutrophil count relates to infarct size and fatal outcome after large hemispheric infarctionCNS Neuroscience & Therapeutics, 2020
- Intravenous thrombolytic therapy for acute ischemic stroke in Hubei, China: a survey of thrombolysis rate and barriersBMC Neurology, 2019
- Neutrophil α-defensins promote thrombosis in vivo by altering fibrin formation, structure, and stabilityBlood, 2019
- Factors Associated With Ischemic Stroke Survival and Recovery in Older AdultsStroke, 2017
- ASPECTS-based reperfusion status on arterial spin labeling is associated with clinical outcome in acute ischemic stroke patientsJournal of Cerebral Blood Flow & Metabolism, 2017
- Inflammatory and metalloproteinases profiles predict three-month poor outcomes in ischemic stroke treated with thrombolysisJournal of Cerebral Blood Flow & Metabolism, 2017
- Leukoaraiosis, intracerebral hemorrhage, and functional outcome after acute stroke thrombolysisNeurology, 2017
- Treatment and Outcome of Thrombolysis-Related HemorrhageJAMA Neurology, 2015
- Higher neutrophil counts before thrombolysis for cerebral ischemia predict worse outcomesNeurology, 2015
- Development and validation of a simplified Stroke–Thrombolytic Predictive InstrumentNeurology, 2015